Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 11/20 | 0.53 |
| ▸ | MME | P08473 | 6/20 | 0.53 |
| ▸ | CASP1 | P29466 | 3/20 | 0.51 |
| ▸ | BCL2L11 | O43521 | 1/20 | 0.51 |
| ▸ | BCL2 | P10415 | 1/20 | 0.51 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.51 |
| ▸ | XIAP | P98170 | 2/20 | 0.50 |
| ▸ | IL1B | P01584 | 1/20 | 0.50 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.49 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13139826 | 1.00 | ACE (0.53) | ACEMMECASP1BCL2L11BCL2 | |
| SCHEMBL10200768 | 0.85 | ACE (0.67) | ACEMMEABCB11AGTR2PDE3A | |
| SCHEMBL647991 | 0.84 | CASP1 (0.50) | CASP1XIAPIL1B | |
| SCHEMBL10248566 | 0.84 | CASP1 (0.50) | CASP1XIAPIL1B | |
| SCHEMBL647990 | 0.84 | CASP1 (0.50) | CASP1XIAPIL1B | |
| SCHEMBL647989 | 0.84 | CASP1 (0.50) | CASP1XIAPIL1B | |
| SCHEMBL13637751 | 0.84 | CASP1 (0.53) | CASP1XIAPIL1B | |
| SCHEMBL13776633 | 0.82 | CASP1 (0.53) | ACEMMECASP1 | |
| SCHEMBL10200771 | 0.80 | XIAP (0.56) | ACEMMEXIAPABCB11AGTR2 | |
| SCHEMBL13197094 | 0.77 | CASP1 (0.43) | CASP1BCL2L11BCL2MCL1XIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120238749-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-09-20 | — | — | US | disclosed |
| US-20120165319-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-28 | — | — | US | disclosed |
| US-20110015371-A1 | Inhibitors of interleukin-1 beta converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-01-20 | — | — | US | disclosed |
| US-7772366-B2 | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-10 | — | — | US | disclosed |
| US-20080070953-A1 | Inhibitors of interleukin-1 beta converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070953-A1 | Inhibitors of interleukin-1 beta converting enzyme | IL1B, IL1A, IL1R1 | ACE 6/4885MME 97/4885CASP1 5/4885 |
| US-20120165319-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | IL1A, IFNAR1, IL1B | ACE 16/4885MME 279/4885CASP1 6/4885 |
| US-20110015371-A1 | Inhibitors of interleukin-1 beta converting enzyme | IL1B, IL1A, IL1R1 | ACE 6/4885MME 97/4885CASP1 5/4885 |
| US-20120238749-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | IL1B, IL1A, IL1R1 | ACE 6/4885MME 97/4885CASP1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.